Scholarlink

<p>The epidermal growth factor receptor (EGFR) is overexpressed in various cancers and contributes to tumor progression and therapeutic resistance. Although EGFR-targeting small-molecule inhibitors are clinically available, their limited efficacy and acquired resistance pose major challenges. In this study, we designed and synthesized a novel class of dual proteolysis-targeting chimeras (PROTACs) incorporating the natural product derivative Potassium Dehydroandrographolide Succinate (PDS) as the protein of interest (POI) ligand. PDS was selected as the POI ligand due to its structural similarity to andrographolide, a natural compound known to inhibit EGFR signaling, suggesting that PDS may retain EGFR-binding potential despite lacking direct anti-tumor reports. Unlike conventional PROTACs, these molecules feature two CRBN E3 ligase ligands symmetrically attached via distinct linkers, thereby enhancing the likelihood of ternary complex formation and promoting more efficient EGFR degradation. Among the synthesized compounds, DP6 exhibited the most potent anti-proliferative activity in MCF-7 cells, with a 3.8-fold improvement over the parent PDS molecule. Western blotting confirmed that DP6 induced concentration-dependent EGFR degradation via the ubiquitin–proteasome system, suppressed downstream JAK2-STAT3 signaling, and promoted apoptosis. This study not only demonstrates the feasibility of utilizing structurally modified natural products as POI ligands, but also introduces a unique dual-ligand PROTAC architecture that may provide enhanced degradation potency for traditionally “undruggable” targets.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual-PROTACs based on natural product derivative potassium dehydrographolide succinate: design, synthesis, and antitumor activity of a novel EGFR degrader

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Ruling Shi,
  • Peixi Zhang,
  • Ming Chen,
  • Weiming Lu,
  • Meng Xu,
  • Huagong Zeng,
  • Jie He,
  • Yan Wang,
  • Yirong Lin,
  • Jieqing Liu

摘要

The epidermal growth factor receptor (EGFR) is overexpressed in various cancers and contributes to tumor progression and therapeutic resistance. Although EGFR-targeting small-molecule inhibitors are clinically available, their limited efficacy and acquired resistance pose major challenges. In this study, we designed and synthesized a novel class of dual proteolysis-targeting chimeras (PROTACs) incorporating the natural product derivative Potassium Dehydroandrographolide Succinate (PDS) as the protein of interest (POI) ligand. PDS was selected as the POI ligand due to its structural similarity to andrographolide, a natural compound known to inhibit EGFR signaling, suggesting that PDS may retain EGFR-binding potential despite lacking direct anti-tumor reports. Unlike conventional PROTACs, these molecules feature two CRBN E3 ligase ligands symmetrically attached via distinct linkers, thereby enhancing the likelihood of ternary complex formation and promoting more efficient EGFR degradation. Among the synthesized compounds, DP6 exhibited the most potent anti-proliferative activity in MCF-7 cells, with a 3.8-fold improvement over the parent PDS molecule. Western blotting confirmed that DP6 induced concentration-dependent EGFR degradation via the ubiquitin–proteasome system, suppressed downstream JAK2-STAT3 signaling, and promoted apoptosis. This study not only demonstrates the feasibility of utilizing structurally modified natural products as POI ligands, but also introduces a unique dual-ligand PROTAC architecture that may provide enhanced degradation potency for traditionally “undruggable” targets.